Symbols / ACET
ACET Chart
About
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 70.42M |
| Enterprise Value | -13.18M | Income | -115.01M | Sales | — |
| Book/sh | 19.04 | Cash/sh | 10.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 152 | IPO | — |
| P/E | — | Forward P/E | -0.66 | PEG | — |
| P/S | — | P/B | 0.39 | P/C | — |
| EV/EBITDA | 0.12 | EV/Sales | — | Quick Ratio | 5.45 |
| Current Ratio | 5.62 | Debt/Eq | 14.23 | LT Debt/Eq | — |
| EPS (ttm) | -20.00 | EPS next Y | -11.09 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -39.13% |
| ROE | -71.73% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.60M |
| Shs Float | 6.83M | Short Float | 8.57% | Short Ratio | 3.57 |
| Short Interest | — | 52W High | 17.44 | 52W Low | 6.41 |
| Beta | 1.56 | Avg Volume | 197.28K | Volume | 40.49K |
| Target Price | $61.50 | Recom | None | Prev Close | $7.36 |
| Price | $7.33 | Change | -0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$61.50
Mean price target
2. Current target
$7.34
Latest analyst target
3. DCF / Fair value
$-109.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.34
Low
$18.00
High
$128.00
Mean
$61.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2026-01-06 | main | Canaccord Genuity | Buy → Buy | $18 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-08 | main | Guggenheim | Buy → Buy | $8 |
| 2025-09-19 | reit | Guggenheim | Buy → Buy | $7 |
| 2025-03-21 | reit | Guggenheim | Buy → Buy | $7 |
| 2025-03-07 | reit | Citizens Capital Markets | Market Perform → Market Perform | — |
| 2025-03-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-06 | reit | JMP Securities | Market Perform → Market Perform | — |
| 2025-02-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-19 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-18 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-14 | main | Canaccord Genuity | Buy → Buy | $19 |
| 2024-07-08 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-23 | reit | Wedbush | Outperform → Outperform | $5 |
- Adicet Bio (ACET) Price Target Increased by 20.00% to 7.75 - Nasdaq Sun, 16 Nov 2025 08
- Adicet Bio (Nasdaq: ACET) issues options for 20,600 shares at $0.65 exercise price - Stock Titan Fri, 28 Nov 2025 08
- Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - Yahoo Finance ue, 30 Sep 2025 07
- $ACET stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- Fed Watch: Is ACET a defensive stock - Quarterly Portfolio Report & Technical Pattern Based Signals - baoquankhu1.vn Wed, 25 Feb 2026 09
- Orbimed advisors buys Adicet Bio (ACET) shares worth $5 million - Investing.com Fri, 10 Oct 2025 07
- Adicet Bio shareholders approve flexible reverse stock split - MSN Fri, 19 Dec 2025 08
- Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat hu, 05 Feb 2026 08
- Adicet Bio (ACET) Price Target Increased by 1,210.53% to 101.59 - Nasdaq Wed, 14 Jan 2026 08
- 70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan ue, 07 Oct 2025 07
- Adicet Bio (ACET) Upgraded to Buy: Here's Why - Yahoo Finance ue, 12 Aug 2025 07
- Guggenheim raises Adicet Bio stock price target on positive lupus data - Investing.com ue, 07 Oct 2025 07
- Biotech CEO’s Guggenheim 2026 summit talk to stream live - Stock Titan Fri, 30 Jan 2026 08
- HC Wainwright & Co. Maintains Adicet Bio (ACET) Buy Recommendation - Nasdaq Fri, 07 Nov 2025 08
- We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Yahoo Finance Sun, 27 Apr 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000000 | 5000000.0 | — | Purchase at price 1.00 per share. | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-08 00:00:00 | I |
| 1 | 5900 | nan | — | — | DUBIN STEVE | Director | — | 2025-06-11 00:00:00 | D |
| 2 | 5900 | nan | — | — | CHODAKEWITZ JEFFREY A. M.D. | Director | — | 2025-06-11 00:00:00 | D |
| 3 | 5900 | nan | — | — | SINCLAIR ANDREW | Director | — | 2025-06-11 00:00:00 | D |
| 4 | 5900 | nan | — | — | KLICKSTEIN LLOYD | Director | — | 2025-06-11 00:00:00 | D |
| 5 | 5900 | nan | — | — | PENG KATIE | Director | — | 2025-06-11 00:00:00 | D |
| 6 | 5900 | 8437.0 | — | Sale at price 1.43 per share. | KAUFFMAN MICHAEL G | Director | — | 2024-06-05 00:00:00 | D |
| 7 | 5900 | nan | — | — | DUBIN STEVE | Director | — | 2024-06-05 00:00:00 | D |
| 8 | 5900 | nan | — | — | KAUFFMAN MICHAEL G | Director | — | 2024-06-05 00:00:00 | D |
| 9 | 5900 | nan | — | — | GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -110.65M | -117.07M | -67.14M | -60.41M |
| TotalUnusualItems | 0.00 | -19.46M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -19.46M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -117.12M | -142.66M | -69.79M | -62.00M |
| ReconciledDepreciation | 6.47M | 6.10M | 2.58M | 1.54M |
| EBITDA | -110.65M | -136.53M | -67.14M | -60.41M |
| EBIT | -117.12M | -142.63M | -69.71M | -61.95M |
| NetInterestIncome | 10.71M | 9.95M | 3.68M | -85.00K |
| InterestExpense | 4.00K | 25.00K | 80.00K | 176.00K |
| InterestIncome | 10.71M | 9.98M | 3.76M | 91.00K |
| NormalizedIncome | -117.12M | -123.20M | -69.79M | -62.00M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -117.12M | -142.66M | -69.79M | -62.00M |
| TotalExpenses | 127.61M | 132.58M | 97.54M | 71.16M |
| TotalOperatingIncomeAsReported | -127.61M | -152.04M | -72.55M | -61.43M |
| DilutedAverageShares | 5.49M | 2.69M | 2.57M | 1.93M |
| BasicAverageShares | 5.49M | 2.69M | 2.57M | 1.93M |
| DilutedEPS | -21.28 | -52.96 | -27.20 | -32.00 |
| BasicEPS | -21.28 | -52.96 | -27.20 | -32.00 |
| DilutedNIAvailtoComStockholders | -117.12M | -142.66M | -69.79M | -62.00M |
| NetIncomeCommonStockholders | -117.12M | -142.66M | -69.79M | -62.00M |
| NetIncome | -117.12M | -142.66M | -69.79M | -62.00M |
| NetIncomeIncludingNoncontrollingInterests | -117.12M | -142.66M | -69.79M | -62.00M |
| NetIncomeContinuousOperations | -117.12M | -142.66M | -69.79M | -62.00M |
| TaxProvision | 0.00 | 0.00 | 0.00 | -125.00K |
| PretaxIncome | -117.12M | -142.66M | -69.79M | -62.12M |
| OtherIncomeExpense | -217.00K | -20.04M | -919.00K | -606.00K |
| OtherNonOperatingIncomeExpenses | -217.00K | -573.00K | -919.00K | -606.00K |
| SpecialIncomeCharges | 0.00 | -19.46M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 19.46M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 10.71M | 9.95M | 3.68M | -85.00K |
| InterestExpenseNonOperating | 4.00K | 25.00K | 80.00K | 176.00K |
| InterestIncomeNonOperating | 10.71M | 9.98M | 3.76M | 91.00K |
| OperatingIncome | -127.61M | -132.58M | -72.55M | -61.43M |
| OperatingExpense | 127.61M | 132.58M | 97.54M | 71.16M |
| ResearchAndDevelopment | 99.32M | 106.04M | 71.25M | 48.94M |
| SellingGeneralAndAdministration | 28.29M | 26.53M | 26.30M | 22.22M |
| GeneralAndAdministrativeExpense | 28.29M | 26.53M | 26.30M | 22.22M |
| OtherGandA | 28.29M | 26.53M | 26.30M | 22.22M |
| TotalRevenue | 0.00 | 0.00 | 24.99M | 9.73M |
| OperatingRevenue | 0.00 | 0.00 | 24.99M | 9.73M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.16M | 2.70M | 2.68M | 2.48M |
| ShareIssued | 5.16M | 2.70M | 2.68M | 2.48M |
| TotalDebt | 17.23M | 20.92M | 21.02M | 20.94M |
| TangibleBookValue | 186.61M | 170.18M | 272.88M | 283.67M |
| InvestedCapital | 186.61M | 170.18M | 292.34M | 303.13M |
| WorkingCapital | 160.74M | 142.99M | 241.33M | 266.12M |
| NetTangibleAssets | 186.61M | 170.18M | 272.88M | 283.67M |
| CapitalLeaseObligations | 17.23M | 20.92M | 21.02M | 20.94M |
| CommonStockEquity | 186.61M | 170.18M | 292.34M | 303.13M |
| TotalCapitalization | 186.61M | 170.18M | 292.34M | 303.13M |
| TotalEquityGrossMinorityInterest | 186.61M | 170.18M | 292.34M | 303.13M |
| StockholdersEquity | 186.61M | 170.18M | 292.34M | 303.13M |
| GainsLossesNotAffectingRetainedEarnings | 16.00K | 0.00 | 0.00 | 0.00 |
| OtherEquityAdjustments | 16.00K | |||
| RetainedEarnings | -497.89M | -380.77M | -238.11M | -168.32M |
| AdditionalPaidInCapital | 684.48M | 550.94M | 530.45M | 471.45M |
| CapitalStock | 8.00K | 4.00K | 4.00K | 4.00K |
| CommonStock | 8.00K | 4.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 33.61M | 37.12M | 38.35M | 35.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 14.22M | 17.83M | 18.64M | 19.49M |
| OtherNonCurrentLiabilities | 116.00K | 130.00K | 114.00K | 115.00K |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 14.10M | 17.70M | 18.53M | 19.38M |
| LongTermCapitalLeaseObligation | 14.10M | 17.70M | 18.53M | 19.38M |
| CurrentLiabilities | 19.39M | 19.29M | 19.71M | 16.32M |
| CurrentDeferredLiabilities | 0.00 | 4.80M | ||
| CurrentDeferredRevenue | 0.00 | 4.80M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.13M | 3.22M | 2.49M | 1.57M |
| CurrentCapitalLeaseObligation | 3.13M | 3.22M | 2.49M | 1.57M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.11M | 6.51M | 5.70M | 4.02M |
| PayablesAndAccruedExpenses | 9.15M | 9.55M | 11.51M | 5.92M |
| CurrentAccruedExpenses | 4.32M | 6.93M | 7.11M | 2.66M |
| Payables | 4.83M | 2.62M | 4.40M | 3.26M |
| AccountsPayable | 4.83M | 2.62M | 4.40M | 3.26M |
| TotalAssets | 220.22M | 207.29M | 330.69M | 338.94M |
| TotalNonCurrentAssets | 40.08M | 45.02M | 69.65M | 56.50M |
| OtherNonCurrentAssets | 3.33M | 822.00K | 1.21M | 2.04M |
| InvestmentsAndAdvances | 0.00 | |||
| InvestmentinFinancialAssets | 0.00 | |||
| HeldToMaturitySecurities | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 19.46M | 19.46M | |
| Goodwill | 0.00 | 19.46M | 19.46M | |
| NetPPE | 36.75M | 44.20M | 48.98M | 35.00M |
| AccumulatedDepreciation | -21.32M | -14.85M | -8.75M | -6.33M |
| GrossPPE | 58.07M | 59.05M | 57.73M | 41.33M |
| Leases | 28.23M | 26.64M | 19.96M | 1.61M |
| ConstructionInProgress | 198.00K | 265.00K | 9.29M | 13.01M |
| OtherProperties | 28.09M | 30.59M | 27.77M | 25.86M |
| MachineryFurnitureEquipment | 1.55M | 1.55M | 709.00K | 839.00K |
| BuildingsAndImprovements | 20.36M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 180.14M | 162.27M | 261.04M | 282.44M |
| OtherCurrentAssets | 474.00K | 457.00K | 336.00K | 2.00K |
| PrepaidAssets | 3.36M | 2.10M | 2.61M | 4.68M |
| Receivables | 0.00 | 435.00K | 214.00K | |
| TaxesReceivable | 0.00 | |||
| AccruedInterestReceivable | 0.00 | 435.00K | 29.00K | |
| AccountsReceivable | 0.00 | 185.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 176.30M | 159.71M | 257.66M | 277.54M |
| OtherShortTermInvestments | 119.81M | 0.00 | 0.00 | |
| CashAndCashEquivalents | 56.49M | 159.71M | 257.66M | 277.54M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -93.50M | -98.18M | -61.55M | -64.10M |
| IssuanceOfCapitalStock | 110.92M | 0.00 | 43.36M | 238.13M |
| CapitalExpenditure | -1.12M | -4.46M | -16.78M | -13.05M |
| IncomeTaxPaidSupplementalData | 0.00 | 43.00K | ||
| EndCashPosition | 59.40M | 159.71M | 257.66M | 277.69M |
| BeginningCashPosition | 159.71M | 257.66M | 277.69M | 88.86M |
| ChangesInCash | -100.31M | -97.94M | -20.04M | 188.84M |
| FinancingCashFlow | 111.31M | 236.00K | 41.51M | 242.69M |
| CashFlowFromContinuingFinancingActivities | 111.31M | 236.00K | 41.51M | 242.69M |
| NetOtherFinancingCharges | -141.00K | -150.00K | -3.60M | -261.00K |
| ProceedsFromStockOptionExercised | 530.00K | 386.00K | 1.75M | 4.82M |
| NetCommonStockIssuance | 110.92M | 0.00 | 43.36M | 238.13M |
| CommonStockIssuance | 110.92M | 0.00 | 43.36M | 238.13M |
| InvestingCashFlow | -119.24M | -4.46M | -16.78M | -2.80M |
| CashFlowFromContinuingInvestingActivities | -119.24M | -4.46M | -16.78M | -2.80M |
| NetInvestmentPurchaseAndSale | -118.12M | 0.00 | 0.00 | 10.25M |
| SaleOfInvestment | 11.00M | 0.00 | 0.00 | 10.25M |
| PurchaseOfInvestment | -129.12M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -1.12M | -4.46M | -16.78M | -13.05M |
| PurchaseOfPPE | -1.12M | -4.46M | -16.78M | -13.05M |
| OperatingCashFlow | -92.38M | -93.72M | -44.77M | -51.05M |
| CashFlowFromContinuingOperatingActivities | -92.38M | -93.72M | -44.77M | -51.05M |
| ChangeInWorkingCapital | -5.53M | 252.00K | 2.74M | -6.06M |
| ChangeInOtherWorkingCapital | -4.80M | -9.18M | ||
| ChangeInOtherCurrentLiabilities | -3.69M | -99.00K | -2.26M | -511.00K |
| ChangeInOtherCurrentAssets | 353.00K | 358.00K | 929.00K | 42.00K |
| ChangeInPayablesAndAccruedExpense | -916.00K | -933.00K | 7.54M | 1.98M |
| ChangeInAccruedExpense | -2.02M | 750.00K | 5.83M | 846.00K |
| ChangeInPayable | 1.11M | -1.68M | 1.71M | 1.14M |
| ChangeInAccountPayable | 1.11M | -1.68M | 1.71M | 1.14M |
| ChangeInPrepaidAssets | -1.27M | 926.00K | 1.34M | 1.63M |
| ChangeInReceivables | 185.00K | -30.00K | ||
| ChangesInAccountReceivables | 185.00K | -30.00K | ||
| OtherNonCashItems | 3.24M | 2.87M | 2.53M | 1.72M |
| StockBasedCompensation | 22.23M | 20.26M | 17.13M | 12.51M |
| AssetImpairmentCharge | 0.00 | 19.46M | 0.00 | 1.19M |
| AmortizationOfSecurities | -1.67M | 0.00 | 0.00 | 10.00K |
| DepreciationAmortizationDepletion | 6.47M | 6.10M | 2.58M | 1.54M |
| DepreciationAndAmortization | 6.47M | 6.10M | 2.58M | 1.54M |
| OperatingGainsLosses | -4.00K | 54.00K | 31.00K | |
| GainLossOnSaleOfPPE | 0.00 | -4.00K | 54.00K | 31.00K |
| NetIncomeFromContinuingOperations | -117.12M | -142.66M | -69.79M | -62.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACET
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|